Navigation Links
Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
Date:9/19/2007

Prodrugs Generated from Targanta's Novel Drug Discovery Platform

CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released detailed data from two studies highlighting the in vitro activity and in vivo efficacy of its proprietary prodrugs in osteomyelitis models. Results are being presented today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago, IL and represent the first data sets from this proprietary platform.

Osteomyelitis is an acute or chronic bone infection predominantly caused by staphylococci, requiring treatment through prolonged parenteral antibiotic administration and, often, surgical intervention. There are currently no antibiotics approved to treat osteomyelitis, which has been designated by the U.S. Food and Drug Administration (FDA) as a significant unmet medical need. Targanta has developed a novel drug discovery platform through which it tethers bone-targeting bisphosphonates to approved antibiotics to generate molecules that deliver the antibiotics directly to the bone, targeting the site of infection.

In the first study, entitled, "Preparation and In Vitro Evaluation of Fluoroquinolone Prodrugs for the Prevention and Treatment of Osteomyelitis," researchers synthesized a total of 45 bisphosphonated fluoroquinolone prodrugs by tethering ciprofloxacin, gatifloxacin or moxifloxacin to a bisphosphonate via cleavable linkers. The affinity of the prodrugs for bone was determined by exposing individual compounds to a suspension of bovine bone powder. Most were found to bind near quantitatively to bone powder and released the parent fluoroquinolone at various rates. In this in vitro study, the high affinity displayed by the compounds for bone powder and their ability to regenerate active parent compound over time suggests they could be used to concentrate antibacterial fluoroquinolones into the bone via systemic administration.

In
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... DANVERS, Mass. , Aug. 27, 2014 North ... with a prestigious R&D 100 Award for the new OSRAM ... laser and LED-based white light module for microscopy, endoscopy and ... Xenon lamps with significantly higher efficacy and lamp life. ... as one of the most innovative new technologies of ...
(Date:8/27/2014)... Aug. 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... of pharmaceutical development, clinical trial manufacturing, and advanced analytical ... that it will participate at the upcoming Rodman & ... be held in New York . ... on September 9, 2014 at the New York Palace ...
(Date:8/27/2014)... 27, 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... following financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over ... loss for the quarter of $240,156 compared to net income ... For the nine months ended June 30, ...
Breaking Medicine Technology:OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
... Medicaid and the State of Alabama are partnering with ... infrastructure for a statewide health information exchange (HIE) that ... (Logo: http://photos.prnewswire.com/prnh/20090507/NY12658LOGO) The partnership is ... diverse group of stakeholders into functional, user-friendly design for ...
... /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) ("Lotus" ... medicine and drugs in the People,s Republic of China ("PRC"), ... ended September 30, 2011. Summary financial data is provided below: ... Financial Highlights Revenues for the ...
Cached Medicine Technology:Alabama Selects Thomson Reuters HIE Advantage™ for Statewide Health Information Exchange 2Alabama Selects Thomson Reuters HIE Advantage™ for Statewide Health Information Exchange 3Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 2Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 3Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 4Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 5Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results 6
(Date:8/27/2014)... Silver Spring, Md. (PRWEB) August 27, 2014 ... Physicians (CHEST) recently released guidelines for the management ... adults, Pharmacological Therapy for Pulmonary Arterial Hypertension in ... guidelines are free to view for clinicians, and ... for PAH. , The Pulmonary Hypertension Association ...
(Date:8/27/2014)... Dennis Thompson HealthDay ... Someone who has been mugged in a dark alley will ... with a fear of being attacked. But neuroscientists working ... how memories are linked with positive and negative emotions. And ... emotions attached to a memory. In essence, they made ...
(Date:8/27/2014)... Warren, MI (PRWEB) August 27, 2014 Michigan ... to help the children of a local elementary school by ... year. Siersma Elementary School has year-round attendance, and Michigan Head ... equipped to meet the new school year. , "There are ... think this is a great way to give back to ...
(Date:8/27/2014)... August 27, 2014 The federal judge ... ) has extended the deadline for plaintiffs to enroll ... 2014 Order issued by U.S. District Judge David Katz ... enroll in the DePuy ASR Settlement Program must do ... Inc. ASR Hip Implant Products Liability Litigation – MDL ...
(Date:8/27/2014)... (HealthDay News) -- Pouring half a glass of wine at a ... new study. Researchers asked 74 college students and staff to ... that had varying amounts of wine in them. The participants were ... had a "rule of thumb" about how much to pour -- ... from the top -- poured less wine than those without set ...
Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3Health News:'Half a Glass' Rule May Curb Overdrinking 2
... Mismatch occurs between seeing letter and the sound it ... -- New brain scans reveal more about how the ... problem seems to be a mismatch between seeing the ... or vice-versa, said researchers from the University of Maastricht ...
... to heart attacks than their predecessors, researchers say , , THURSDAY, ... good shape, even when compared with their counterparts 10 or ... study, more aging boomers are being hospitalized for heart attacks ... the increase in cases could place a big burden on ...
... Shamir Optical Industry Ltd. (Nasdaq: SHMR ) ("Shamir") ... earnings results on Wednesday, March 18, 2009, and has scheduled ... EDT that morning. The conference call will be broadcast live ... www.kcsa.com approximately five minutes before the conference call ...
... MESSA,s East Lansing-based ... consecutive year for superior efficiency and performance in providing ... providing efficient and effective customer service as measured against ... at Purdue University and BenchmarkPortal. "MESSA is ...
... Care Management Software Applications As Part of Electronic ... TCS Healthcare Technologies (TCS), an industry ... applications, supports the health information technology (IT) provisions ... as the American Recovery and Reinvestment Act of ...
... researchers find aerosol levels have diminished visibility , , THURSDAY, ... of data showing how clear, or unclear, the sky ... air pollution have affected climate change, according to a ... show that what the researchers call clear sky visibility ...
Cached Medicine News:Health News:Brain Scans Shed Light on Dyslexia 2Health News:Brain Scans Shed Light on Dyslexia 3Health News:Aging Baby Boomers May Swamp Cardiac Care 2Health News:Aging Baby Boomers May Swamp Cardiac Care 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Fourth Quarter and Year End 2008 Earnings Results 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 3Health News:TCS Healthcare Technologies Offers Health IT Solutions That Support Health Care Reform 2Health News:TCS Healthcare Technologies Offers Health IT Solutions That Support Health Care Reform 3Health News:Clear Skies Have Become Less So Over Time, Data Show 2
The Fluoroskan Ascent, a dedicated microplate fluorometer, offers high sensitivity for a wide variety of fluorometric applications....
The VersaFluor cuvette fluorometer is a fast and simple way to quantitate DNA, RNA, and proteins, to detect apoptosis, and to perform reporter enzyme assays with the high level of sensitivity and sel...
... unique microprocessor-controlled filter wheels for wavelength selection ... filter wheels can be programmed for excitation ... With this fluorometer, you do not have ... wavelengths. The C&L Dye Fluorometer can measure ...
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
Medicine Products: